Table 2.
Our institutional protocol for the treatment of patients with COVID-19 with pneumonia at the time of case admissiona
| Lopinavir/ritonavir 400 mg/100 mg (2l tablets) twice daily × 10–14 days | |
| PLUS | |
| First line | Hydroxychloroquine |
| Day 1: 400 mg every 12 h | |
| Then 400 mg/day × 9–14 days | |
| OR | |
| Second line: patients intolerant to hydroxychloroquine (i.e., risk of QTc prolongation) | Favipiravir |
| Day 1: 1600 mg (8 tablets) every 12 h (loading dose) | |
| Then 600 mg (3 tablets) every 8 h × 9–14 days | |
COVID-19 coronavirus 2019 (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), QTc corrected QT interval
aOur current protocol recommends favipiravir as first-line therapy for the treatment of mildly symptomatic COVID-19 (mild pneumonia, no cytokine storm, and patient not on supplemental oxygen). Hydroxychloroquine and lopinavir/ritonavir are no longer recommended in our protocol; instead, dexamethasone and remdesivir are used in the treatment of severe COVID-19 pneumonia in patients requiring supplemental oxygen